Marc Wagner focuses his practice on regulatory and transactional matters, primarily in the healthcare and life sciences industries. He has experience advising clients on Food and Drug Administration (FDA) regulatory matters, including food, drug, device, dietary supplement and cosmetic issues, as well as matters related to compounding pharmacies operating pursuant to Section 503A of the Federal Food, Drug and Cosmetic Act (FD&C Act) and outsourcing facilities operating pursuant to Section 503B of the FD&C Act.
